In the News

IFM Expands Leadership Team to Address the Worldwide Epidemic of Chronic Disease

Wholistic Nutrition Leader Standard Process Inc. (Palmyra, WI) Holds Grand Opening for Innovation and Research Center in Kannapolis, NC, Lt. Governor Dan Forest Among VIP Attendees and Speakers

NEW MENAQ7® VITAMIN K2 HUMAN STUDY IN AORTIC CALCIFICATION IN LEADING JOURNAL NUTRIENTS

IFM Expands Leadership Team to Address the Worldwide Epidemic of Chronic Disease

The Institute for Functional Medicine (IFM) has taken another significant step toward expanding its executive leadership capabilities by naming Cary Sennett, MD, PhD, as president of Medical Education and Research, a new senior role created by IFM to advance the critical work of evaluating and integrating emerging research and trends in health and medicine and to catalyze broad-based partnerships to further mature the Functional Medicine curriculum, clinical model, and evidence base.

This development, combined with the recent appointment of Amy R. Mack as the new chief executive officer (CEO) and the ascension of former CEO Laurie Hofmann, MPH, to chairman of the board, enables the organization to better address a broader agenda beyond education—including researching innovative and economic clinical models and broad-based strategic partnerships.

Dr. Sennett, a board certified internist and fellow of the American College of Physicians (FACP), comes to IFM from a long career in health care as a practitioner and administrator, most recently as president and CEO at the Asthma and Allergy Foundation of America. He received his PhD in health policy and management from MIT, his MD and MPhil (in human genetics) from Yale, and his BS in biology from Stanford.

“As a healthcare professional for over 30 years, my personal mission has always been to provide healthcare solutions for patients that effectively treat their conditions at a cost that makes quality health care accessible and affordable,” says Dr. Sennett. “We are at a critical time in our country where the cost of our healthcare system substantially outweighs the value and positive outcomes it provides the average patient. What drew me to IFM—and more generally to Functional Medicine—is the evidence that Functional Medicine provides a path forward to create an affordable healthcare model based on individualized, patient-centered care that delivers optimal results in addressing chronic diseases and restoring health.”

Dr. Sennett’s immediate priorities include enhancing the Functional Medicine evidence base and continuing to drive greater accessibility and innovation of the organization’s educational programs in alignment with IFM’s strategic plan. He will also accelerate IFM’s online learning capability and outcomes research programs to strengthen the evidence base for Functional Medicine.

“We are excited Dr. Sennett is joining our team at this critical moment for Functional Medicine. His expertise is required as IFM builds on its already strong foundation as best in class educator and innovator in Functional Medicine and reinforces its role in shaping health care in the United States and around the world,” says Mack. “Dr. Sennett will play an integral role in catalyzing the evidence base and research to demonstrate Functional Medicine’s effectiveness in identifying and treating the root cause of chronic conditions and diseases and proving both the clinical and economic value for patients.”

“Our strong foundation and 25-year track record as the leader in Functional Medicine, combined with our expanded executive team, will propel IFM to more aggressively support and grow vital partnerships across academic medicine, health systems, self-insured employers, and educational coalitions,” says Hofmann. “This will facilitate broader and faster adoption of Functional Medicine as an important and much-needed component in promoting health and reversing the epidemic of chronic disease.”

Wholistic Nutrition Leader Standard Process Inc. (Palmyra, WI) Holds Grand Opening for Innovation and Research Center in Kannapolis, NC, Lt. Governor Dan Forest Among VIP Attendees and Speakers

First-of-Kind Facility to Pursue Innovation in Nutritional Therapy, Developing New Solutions for Healthcare Professionals and Patients

PALMYRA, Wis. and KANNAPOLIS/CHARLOTTE, N.C., April 19, 2018 /PRNewswire/ -- With the increased interest in nutritional therapies, sustainable agriculture and integrative healthcare, the need for research on whole food-based clinical nutrition solutions for health is greater than ever. On April 24, Standard Process will hold a grand opening event for its Nutrition Innovation Center, the first-of-kind research and innovation facility with a mission to improve human health and well-being through whole-person clinical care, organic farming and wholistic nutritional therapies. Standard Process is a leading manufacturer of the highest-quality, nutrient-dense therapeutic supplements provided through healthcare professionals across the United States.

In addition to executives from Standard Process, attending the opening and tour will be North Carolina's Lt. Governor Dan Forest; William Pilkington DPA, MPA, MA, CEO and director of public health, Cabarrus Health Alliance; and Mary Ann Lila, Ph.D., director, Plants for Human Health Institute and professor, North Carolina State University. Also in attendance will be many healthcare professionals who have used Standard Process products in their practices. Following the ribbon-cutting, there will be by-invitation-only tours and a three-hour seminar, "The Future of Integrative Healthcare" featuring clinical experts.

"Standard Process has been a leader and innovator in whole food nutrition for nine decades," says Charles DuBois, Standard Process president and CEO. "The Nutrition Innovation Center will be the leading and only active clinical research center of its kind, dedicated to both mid- and long-term support of whole food clinical nutrition. We are excited about being in North Carolina, and becoming an active and productive contributor to the region."

"What makes the Nutrition Innovation Center unique and so relevant to today's healthcare needs is that it is dedicated to the intersection of whole-person clinical care, nutritional therapies and organic agriculture," says John Troup, Standard Process VP of clinical science, education and innovation, and head of the new Standard Process Nutrition Innovation Center. "We will be focusing on developing advances in nutrition-based therapeutic care as well as conducting original clinical research demonstrating improved patient outcomes – all in support of integrative and wholistic healthcare practitioners."

According to Troup, the center, located at NC Research Campus just north of Charlotte in Kannapolis (North Carolina Research Campus, David H. Murdock Core Laboratory Building), spans 10,000 square feet, housing four major programs:

• Discovery innovation research focused on preclinical, systems biology and cell models that advance information on targeted effects of phytonutrients and nutritional solutions;
• A clinical development and research program defined by a coalition of collaborating clinical research sites that establishes a network for practice-based and case-observation studies conducted on a national basis;
• A professional media and learning center that will provide the most advanced educational tools and capabilities that will transform healthcare practitioner education and training;
• The Clinic of the Future, an integrative and functional clinical program bringing together multiple credentialed health professionals at one site where training on the practical and relevant aspects of clinical nutrition therapies are offered for all levels of practitioners.

North Carolina's Lt. Governor Dan Forest will be on hand for the April 24 ribbon-cutting and opening ceremony, beginning at 10 a.m. Forest has been a longtime leader of the business community and, as Lt. Governor, serves on the state's Food Manufacturing Task Force, among other forward-thinking initiatives.

About Standard Process Inc.
Standard Process is a family-owned company dedicated to making high-quality and nutrient-dense therapeutic supplements for three generations. Standard Process focuses on achieving wholistic health through nutrition. From their organic, regenerative farming practice to their Nutrition Innovation Center research facility, Standard Process is committed to clinical science that advances health and transforms lives. From soil to supplement, there is a direct relationship between the earth, food consumed and overall well-being.

Guided by the whole food philosophy of its founder Dr. Royal Lee, Standard Process seeks to provide nutrients as found in nature, which Lee believed offered the highest natural potency and efficacy. Today Standard Process proudly carries on Dr. Lee's legacy and regularly grows more than 80 percent of the raw plant ingredients found in its products on its certified organic farm in Palmyra, Wisconsin. Using state-of-the-art manufacturing processes to retain vital nutrients within each ingredient, Standard Process manufactures its supplements in its certified organic manufacturing facility. Standard Process employs high quality control standards and follows the Food and Drug Administration's good manufacturing practices. https://www.standardprocess.com/

About the North Carolina Research Campus

The North Carolina Research Campus, located in Kannapolis, N.C., near Charlotte, has the mission of improving human health through nutrition. Our scientific community of eight universities, the David H. Murdock Research Institute, global companies and entrepreneurs focus research and development on safer, more nutritious crops, healthier foods and precision nutrition. Learn more at https://transforming-science.com/.

About Lt. Governor Dan Forest

North Carolina Lt. Governor since January 2013, Dan earned his architecture degree from UNC-Charlotte and was a leader in the business community for over 20 years. As Lt. Governor, Dan serves as the president of the North Carolina Senate and is a voting member of the State Board of Education and the State Board of Community Colleges. On the State Board of Education, he is the chairman of the Special Committee on Digital Technology, which is tasked with the implementation of the statewide digital technology plan. He is also a member of the NC Advisory Commission on Military Affairs, the Food Manufacturing Task Force and serves as chairman of the Energy Policy Council and the Board of Post-Secondary Credentials.

Contact Chuck Robbins, Email: crobbins@consultaro.com, phone or text 704.839.3520

Related Images

nc-research-campus.jpg
NC Research Campus
First-of-Kind Facility to Pursue Innovation in Nutritional Therapy, Developing New Solutions for Healthcare Professionals and Patients While Advancing the Science of Whole Food Nutrition.

ceo-standard-process-inc.jpg
CEO Standard Process Inc.
Charlie Dubois, CEO of Standard Process Inc.

catalyn.gif
CataLyn

Related Links

Standard Process

Pure Branding

Related Video

http://www.youtube.com/watch?v=qvFHPhGWFbY

SOURCE Standard Process

NEW MENAQ7® VITAMIN K2 HUMAN STUDY IN AORTIC CALCIFICATION IN LEADING JOURNAL NUTRIENTS

Protocol shows Vitamin K2 treatment on imaging measurements of existing calcification

Oslo, Norway and Edison, NJ (April 4, 2018) — NattoPharma is excited to announce that Nutrients has published a new paper, "Bicuspid Aortic Valve Stenosis and the Effect of Vitamin K2 on Calcification Using 18F-Sodium Fluoride Positron Emission Tomography/Magnetic Resonance: The BASIK2 Rationale and Trial Design", which examines the benefits of MenaQ7® Vitamin K2 as MK-7 for patients with existing calcification.

Being conducted by the expert researchers at Maastricht University Medical Center and CARIM, the double-blind placebo-controlled study will randomize subjects into intervention and control groups, receiving an oral dose of 360 micrograms (mcg) menaquinone-7 (MK-7) or placebo, respectively.  The MK-7 is MenaQ7® (provided by NattoPharma ASA, Oslo, Norway) and the total study duration is 18 months with 44 participants who have bicuspid aortic valve (BAV) and mild–moderate calcific aortic valve stenosis (CAVS).

According to Dr. Leon Schurgers, one of the paper’s authors: "18F-sodiumfluoride positron emission tomography (PET), magnetic resonance (MR) and computed tomography (CT) assessments will be performed showing for the first time providing incremental information to the standard methods (echocardiography and CT) used to measure aortic valve stenosis and calcification.  In essence, the progression or regression of micro-calcification should be clearly observable for the first time."

"This is a breakthrough study for individuals with existing calcifications, and noteworthy as the traditional medical community is initiating a study in diseased patients,” says Dr. Hogne Vik, NattoPharma Chief Medical Officer. "Previously published research in healthy populations show MenaQ7 can inhibit the progression of arterial stiffening, and even regress stiffening resulting in improved arterial flexibility.  Now these researchers are looking to determine if vitamin K2 can regress calcification in patients with CAVS - while the only current treatment is valve replacement."

BAV is associated with early development of CAVS and pathophysiologic mechanisms are incompletely defined. Numerous pharmaceutical therapies have been studied as potential intervention in the progression of CAVS, but have not yet presented successful treatment options. Therefore, the only treatment option currently available for severe CAVS is valve replacement.

“Recognizing that medical therapies are proving ineffective, researchers are shining a light on efficacious supplemental alternatives, which leads them to the clinical research that NattoPharma has spearheaded. Specifically, our three-year cardiovascular study in healthy postmenopausal women taking just 180 mcg daily of Vitamin K2 as MK-7 (as MenaQ7), which demonstrated a cessation and even regression in arterial stiffness.

“The relevance of our three-year study has resulted in several studies by the medical community for patients with existing coronary artery calcification, aortic valve calcification, and peripheral artery calcification,” adds Dr. Vik.

XXX

About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending; and now the new MenaQ7® Full Spectrum, which delivers menaquinones 6, 7, and 9. The company has a multi-year research and development program to substantiate and discover the health benefits of Vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com.

For more information, please contact:

Kate Quackenbush, NattoPharma Director of Communications

Phone: 609-643-0749 x 220

E-mail: kate.quackenbush@nattopharma.com